|
1.
|
Liedtke C, Mazouni C, Hess KR, et al:
Response to neoadjuvant therapy and long-term survival in patients
with triple-negative breast cancer. J Clin Oncol. 26:1275–1281.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Tan DS, Marchió C, Jones RL, Savage K,
Smith IE, Dowsett M and Reis-Filho JS: Triple negative breast
cancer: molecular profiling and prognostic impact in adjuvant
anthracycline-treated patients. Breast Cancer Res Treat. 111:27–44.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Rakha EA, El-Sayed ME, Green AR, Lee AH,
Robertson JF and Ellis IO: Prognostic markers in triple-negative
breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Bauer KR, Brown M, Cress RD, Parise CA and
Caggiano V: Descriptive analysis of estrogen receptor
(ER)-negative, progesterone receptor (PR)-negative, and
HER2-negative invasive breast cancer, the so-called triple-negative
phenotype: a population-based study from the California Cancer
Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar
|
|
5.
|
Haffty BG, Yang Q, Reiss M, Kearney T,
Higgins SA, Weidhaas J, Harris L, Hait W and Toppmeyer D:
Locoregional relapse and distant metastasis in conservatively
managed triple negative early-stage breast cancer. J Clin Oncol.
24:5652–5657. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Carey LA, Perou CM, Livasy CA, et al:
Race, breast cancer subtypes, and survival in the Carolina Breast
Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Carey LA, Dees EC, Sawyer L, Gatti L,
Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou
CM: The triple negative paradox: primary tumor chemosensitivity of
breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Sørlie T, Perou CM, Tibshirani R, et al:
Gene expression patterns of breast carcinomas distinguish tumor
subclasses with clinical implications. Proc Natl Acad Sci USA.
98:10869–10874. 2001.PubMed/NCBI
|
|
10.
|
Sorlie T, Tibshirani R, Parker J, et al:
Repeated observation of breast tumor subtypes in independent gene
expression data sets. Proc Natl Acad Sci USA. 100:8418–8423. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Nielsen TO, Hsu FD, Jensen K, et al:
Immunohistochemical and clinical characterization of the basal-like
subtype of invasive breast carcinoma. Clin Cancer Res.
10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Keam B, Im SA, Kim HJ, et al: Prognostic
impact of clinicopathologic parameters in stage II/III breast
cancer treated with neoadjuvant docetaxel and doxorubicin
chemotherapy: paradoxical features of the triple negative breast
cancer. BMC Cancer. 7:2032007. View Article : Google Scholar
|
|
13.
|
Mazouni C, Peintinger F, Wan-Kau S, Andre
F, Gonzalez Angulo AM, Symmans WF, Meric-Bernstam F, Valero V,
Hortobagyi GN and Pusztai L: Residual ductal carcinoma in situ in
patients with complete eradication of invasive breast cancer after
neoadjuvant chemotherapy does not adversely affect patient outcome.
J Clin Oncol. 25:2650–2655. 2007. View Article : Google Scholar
|
|
14.
|
Tavassoli FA and Devilee P; World Health
Organization: Classification of Tumours: Pathology and Genetics of
Tumours of the Breast and Female Genital Organs. IARC Press; Lyon:
2003
|
|
15.
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar
|
|
16.
|
Kurosumi M: Significance and problems in
evaluations of pathological responses to neoadjuvant therapy for
breast cancer. Breast Cancer. 13:254–259. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Putti TC, El-Rehim DM, Rakha EA, Paish CE,
Lee AH, Pinder SE and Ellis IO: Estrogen receptor-negative breast
carcinomas: a review of morphology and immunophenotypical analysis.
Mod Pathol. 18:26–35. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Livasy CA, Karaca G, Nanda R, Tretiakova
MS, Olopade OI, Moore DT and Perou CM: Phenotypic evaluation of the
basal-like subtype of invasive breast carcinoma. Mod Pathol.
19:264–271. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Kono S, Kurosumi M, Simooka H, Kawanowa K,
Ninomiya J, Takei H, Suemasu K and Kuroda Y: Immunohistochemical
study of the relationship between Ki-67 labeling index of
proliferating cells of gynecomastia, histological phase and
duration of disease. Pathol Int. 56:655–658. 2006. View Article : Google Scholar
|
|
20.
|
Yang Q, Sakurai T, Mori I, Yoshimura G,
Nakamura M, Nakamura Y, Suzuma T, Tamaki T, Umemura T and Kakudo K:
Prognostic significance of BRCA1 expression in Japanese sporadic
breast carcinomas. Cancer. 92:54–60. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Bidard FC, Matthieu MC, Chollet P,
Raoefils I, Abrial C, Dômont J, Spielmann M, Delaloge S, André F
and Penault Llorca F: p53 status and efficacy of primary
anthracyclines/alkylating agent-based regimen according to breast
cancer molecular classes. Ann Oncol. 19:1261–1265. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Geisler S, Lønning PE, Aas T, Johnsen H,
Fluge O, Haugen DF, Lillehaug JR, Akslen LA and Børresen-Dale AL:
Influence of TP53 gene alterations and c-erbB-2 expression on the
response to treatment with doxorubicin in locally advanced breast
cancer. Cancer Res. 61:2505–2512. 2001.PubMed/NCBI
|
|
23.
|
Aas T, Børresen AL, Geisler S,
Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA and Lønning PE:
Specific P53 mutations are associated with de novo resistance to
doxorubicin in breast cancer patients. Nat Med. 2:811–814. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Mieog JS, van der Hage JA, van de Vijuer
MJ and van de Velde CJ; Cooperating Investigators of the EORTC:
Tumour response to preoperative anthracycline-based chemotherapy in
operable breast cancer: the predictive role of p53 expression. Eur
J Cancer. 42:1369–1379. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Colleoni M, Orvieto E, Nolé F, et al:
Prediction of response to primary chemotherapy for operable breast
cancer. Eur J Cancer. 35:574–579. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Bertheau P, Turpin E, Rickman DS, Espié M,
de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de
Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin
A and de Thé H: Exquisite sensitivity of TP53 mutant and basal
breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
PLoS Med. 4:e902007. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Umemura S, Takekoshi S, Suzuki Y, Saitoh
Y, Tokuda Y and Osamura RY: Estrogen receptor-negative and human
epidermal growth factor receptor 2-negative breast cancer tissue
have the highest Ki-67 labeling index and EGFR expression: gene
amplification does not contribute to EGFR expression. Oncol Rep.
14:337–343. 2005.
|
|
28.
|
Nogi H, Kobayashi T, Suzuki M, Tabei I,
Kawase K, Toriumi Y, Fukushima H and Uchida K: EGFR as paradoxical
predictor of chemosensitivity and outcome among triple-negative
breast cancer. Oncol Rep. 21:413–417. 2009.PubMed/NCBI
|
|
29.
|
Tanner M, Isola J, Wiklund T, Erikstein B,
Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J and Bergh
J: Topoisomerase IIalpha gene amplification predicts favorable
treatment response to tailored and dose-escalated
anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified
breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol.
24:2428–2436. 2006. View Article : Google Scholar
|
|
30.
|
Arriola E, Rodriguez-Pinilla SM, Lambros
MB, Jones RL, James M, Savage K, Smith IE, Dowsett M and Reis-Filho
JS: Topoisomerase II alpha amplification may predict benefit from
adjuvant anthracyclines in HER2 positive early breast cancer.
Breast Cancer Res Treat. 106:181–189. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
MacGrogan G, Rudolph P, Mascarel Id I, et
al: DNA topoisomerase IIalpha expression and the response to
primary chemotherapy in breast cancer. Br J Cancer. 89:666–671.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Järvinen TA, Tanner M, Rantanen V, Bärlund
M, Borg A, Grénman S and Isola J: Amplification and deletion of
topoisomerase IIalpha associate with ErbB-2 amplification and
affect sensitivity to topoisomerase II inhibitor doxorubicin in
breast cancer. Am J Pathol. 156:839–847. 2000.PubMed/NCBI
|
|
33.
|
Lynch BJ, Guinee DG Jr and Holden JA:
Human DNA topoisomerase II-alpha: a new marker of cell
proliferation in invasive breast cancer. Hum Pathol. 28:1180–1188.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Järvinen TA, Kononen J, Pelto-Huikko M and
Isola J: Expression of topoisomerase IIalpha is associated with
rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in
breast cancer. Am J Pathol. 148:2073–2082. 1996.PubMed/NCBI
|
